Opendata, web and dolomites

RxmiRcanceR SIGNED

Tumor suppressive microRNAs for cancer therapy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "RxmiRcanceR" data sheet

The following table provides information about the project.

Coordinator
THE HEBREW UNIVERSITY OF JERUSALEM 

Organization address
address: EDMOND J SAFRA CAMPUS GIVAT RAM
city: JERUSALEM
postcode: 91904
website: www.huji.ac.il

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Total cost 2˙840˙729 €
 EC max contribution 2˙840˙729 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-ADG
 Funding Scheme ERC-ADG
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2023-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    THE HEBREW UNIVERSITY OF JERUSALEM IL (JERUSALEM) coordinator 2˙840˙729.00

Map

 Project objective

The challenge for cancer therapy involves hampering the mechanisms by which the normal gene expression machinery is taken over to allow the aberrant appearance of cancer driving genes. I propose exploiting the therapeutic potential of a special class of tumor microRNAs (miRs) that function as natural post-transcriptional tumor suppressive regulators of many genes in key pathways. These anti-cancer effectors represent an inherent organismal property that I propose to augment and thereby translate into a form of systemic anti-cancer therapy. First, focusing on hepatocellular carcinoma (HCC), I shall perform high throughput screening to identify preferred HCC tumor suppressive miRs. Second, I shall search for small molecules capable of elevating the level of those relevant miRs in tumor cells and tissues. Increasing miR expression will potentially also enhance their secretion into the circulation in exosomes thereby suppressing gene expression at remote tissue sites as well. Third, I shall test the potential of these miRs to better target and inhibit the growth of tumor cells both, in culture and in vivo. This unprecedented conceptual strategy should stimulate the organism’s self-healing potential by enhancing inherent anti-tumor mechanisms. This project is built on robust preliminary findings that show promiscuous anti-cancer effects and predictably fewer side effects due to its completely host-based nature, with the administered miR inducer being the only foreign element. Additionally, due to the fact that each miR simultaneously targets a number of molecular pathways as well as multiple steps within a given pathway, it could help to overcome the major problem of cancer therapy – resistance. This strategy of harnessing these efficient and robust miRs and exosomes for delivery of anti-cancer therapeutics may overcome the high-risk challenge involved and enable high gain value.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RXMIRCANCER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "RXMIRCANCER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

MajoranasAreReal (2019)

Search for mechanisms to control chiral Majorana modes in superconductors

Read More  

Mu-MASS (2019)

Muonium Laser Spectroscopy

Read More  

FatVirtualBiopsy (2020)

MRI toolkit for in vivo fat virtual biopsy

Read More